卡巴他赛纳米制剂的研究进展  

Research progress of Cabazitaxel nano-formulations

作　　者：柳宇红 姜宇 郝贵周 刘善奎 LIU Yuhong;JIANG Yu;HAO Guizhou;LIU Shankui(School of Biological Science and Technology,University of Jinan,Jinan,Shandong,250022 P.R.China;Scientific Research Department of Shandong New Era Pharmaceutical Co.,Ltd.,Linyi,Shandong,273400 P.R.China)

机构地区：[1]济南大学生物科学与技术学院,山东济南250022 [2]山东新时代药业有限公司科研部,山东临沂273400

出　　处：《华西药学杂志》2022年第5期578-586,共9页West China Journal of Pharmaceutical Sciences

基　　金：山东省重大科技创新工程项目(No.2019JZZY011116)。

摘　　要：第二代紫杉烷类药物卡巴他赛,具有较低的P-gp亲和力,可用于治疗多西他赛耐药的前列腺癌,是临床上治疗前列腺癌的二线药物。现从新药研发的角度综述卡巴他赛新型纳米剂型的发展现状。Cabazitaxel is a second-generation taxane drug.It has a lower P-gp affinity, it can be used for the treatment of prostate cancer in which Docetaxel is ineffective, and it is a second-line drug for the clinical treatment of prostate cancer.This review aims to discuss the development status of Cabazitaxel new nano dosage forms from the perspective of new drug development.

关 键 词：卡巴他赛 纳米制剂 紫杉醇 多西他赛 脂质体 脂微球 白蛋白纳米粒 聚合物胶束 聚合物-药物共价物纳米粒 口服给药纳米粒 杂化纳米粒 联合治疗 

分 类 号：R94[医药卫生—药剂学]